AstraZeneca, Daiichi Sankyo and ENHERTU

AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast cancer.
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.
AstraZeneca, Daiichi’s drug cleared for wider use in breast cancer patients in US
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the US and European Union for some breast cancer patients whose cancer spread after receiving treatment, or whose disease returned after surgery.
FDA Approves AstraZeneca, Daiichi Sankyo’s Enhertu for Unresectable or Metastatic Hormone Receptor-Positive, HER2-Low Breast Cancer
Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer.
AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment
AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial,
AstraZeneca's Enhertu gets additional FDA approval
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients. Enhertu was approved for the treatment of unresectable or metastatic HR-positive,
FierceBiotech12h
AstraZeneca antibody protects macaques from severe bird flu, suggesting prophylactic potential in case of outbreak
All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...
Zacks.com on MSN1d
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?
AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...
AstraZeneca's SWOT analysis: pharma giant's stock poised for growth amid challenges
AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
AstraZeneca rises Wednesday, outperforms market
AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.
Business Facilities6d
AstraZeneca Will Invest $820M In Ontario R&D Hub
AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario ’s growing ...
Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)
In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...
AstraZeneca PLC ADR rises Monday, outperforms market
The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...
‘I was desperate for the AstraZeneca vaccine to succeed. Then I became alarmed by what I saw’
Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...